miR‑665 is downregulated in glioma and inhibits tumor cell proliferation, migration and invasion by targeting high mobility group box 1

Shen,Hao; Xu,Ling; You,Chunyue; Tang,Huaibo; Wu,Haitao; Zhang,Yong; Xie,Mingxiang

doi:10.3892/ol.2020.12417

miR‑665 is downregulated in glioma and inhibits tumor cell proliferation, migration and invasion by targeting high mobility group box 1

Authors:
- Hao Shen
- Ling Xu
- Chunyue You
- Huaibo Tang
- Haitao Wu
- Yong Zhang
- Mingxiang Xie
View Affiliations

Affiliations: Department of Neurosurgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China
Published online on: December 31, 2020 https://doi.org/10.3892/ol.2020.12417
Article Number: 156

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is the most common brain tumor in adults. microRNAs (miRNAs/miRs) play an essential role in tumor development and progression. The present study aimed to investigate the potential clinical significance and function of miR‑665 in glioma. Reverse transcription‑quantitative PCR analysis was used to detect the expression of miR‑665 in glioma tissues and cells. Survival curves were constructed using the Kaplan‑Meier method. Cox regression analysis was performed to investigate the prognostic significance of miR‑665. Cell Counting Kit‑8 and Transwell assays were used to evaluate the role of miR‑665 in glioma. Bioinformatics analysis and dual‑luciferase reporter assays were used to predict the putative direct targets of miR‑665. Western blotting was used to evaluate the activity of the Wnt/β‑catenin pathway. The relative expression of miR‑665 was decreased in glioma tissues and cells and this downregulation was significantly associated with the Karnofsky performance scale score and World Health Organisation grade. Patients with glioma with low miR‑665 expression had a shorter overall survival time compared with the high expression group. Besides, overexpression of miR‑665 suppressed the proliferation, migration and invasion of glioma cells, while knockdown of miR‑665 promoted these cellular behaviors. High mobility group box (HMGB)1 was a direct target of miR‑665. It was also demonstrated that miR‑665 may suppress glioma progression by targeting HMGB1 and inhibiting the Wnt/β‑catenin pathway. Taken together, these data suggested that miR‑665 may have a tumor suppressor role in glioma by targeting HMGB1. Therefore, miR‑665 may be a novel prognostic biomarker and the miR‑665/HMGB1 axis may be a novel therapeutic target for the treatment of glioma.

View Figures

View References

1	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H, Abbott D, Cannon-Albright L and Cohen AL: The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC Cancer. 19:1902019. View Article : Google Scholar : PubMed/NCBI
3	Iser IC, Pereira MB, Lenz G and Wink MR: The epithelial-to-mesenchymal transition-like process in glioblastoma: An updated systematic review and in silico investigation. Med Res Rev. 37:271–313. 2017. View Article : Google Scholar : PubMed/NCBI
4	Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
5	Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, Kim L and Shi W: Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 117:125–131. 2014. View Article : Google Scholar : PubMed/NCBI
6	Linz U: Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466). Cancer. 116:1844–1846. 2010. View Article : Google Scholar : PubMed/NCBI
7	Arvold ND and Reardon DA: Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging. 9:357–367. 2014.PubMed/NCBI
8	Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kim DY and Sung JH: Regulatory role of microRNAs in the proliferation and differentiation of adipose-derived stem cells. Histol Histopathol. 32:1–10. 2017.PubMed/NCBI
10	Mahmoudian-Sani MR, Jalali A, Jamshidi M, Moridi H, Alghasi A, Shojaeian A and Mobini GR: Long non-coding RNAs in thyroid cancer: Implications for pathogenesis, diagnosis, and therapy. Oncol Res Treat. 42:136–142. 2019. View Article : Google Scholar : PubMed/NCBI
11	Rivera-Barahona A, Pérez B, Richard E and Desviat LR: Role of miRNAs in human disease and inborn errors of metabolism. J Inherit Metab Dis. 40:471–480. 2017. View Article : Google Scholar : PubMed/NCBI
12	Paliouras AR, Monteverde T and Garofalo M: Oncogene-induced regulation of microRNA expression: Implications for cancer initiation, progression and therapy. Cancer Lett. 421:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
13	Wu Y, Song Y, Xiong Y, Wang X, Xu K, Han B, Bai Y, Li L, Zhang Y and Zhou L: MicroRNA-21 (Mir-21) Promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell Physiol Biochem. 43:945–958. 2017. View Article : Google Scholar : PubMed/NCBI
14	Liu DZ, Zhao H, Zou QG and Ma QJ: MiR-338 suppresses cell proliferation and invasion by targeting CTBP2 in glioma. Cancer Biomark. 20:289–297. 2017. View Article : Google Scholar : PubMed/NCBI
15	Svoronos AA, Engelman DM and Slack FJ: OncomiR or tumor suppressor? The duplicity of MicroRNAs in cancer. Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
16	Möhnle P, Schütz SV, Schmidt M, Hinske C, Hübner M, Heyn J, Beiras-Fernandez A and Kreth S: MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure. Biochem Biophys Res Commun. 451:516–521. 2014. View Article : Google Scholar : PubMed/NCBI
17	Tan H, Zhao L, Song R, Liu Y and Wang L: microRNA-665 promotes the proliferation and matrix degradation of nucleus pulposus through targeting GDF5 in intervertebral disc degeneration. J Cell Biochem. 119:7218–7225. 2018. View Article : Google Scholar : PubMed/NCBI
18	Liu NW, Huang X, Liu S and Lu Y: EXT1, regulated by MiR-665, promotes cell apoptosis via ERK1/2 signaling pathway in acute lymphoblastic leukemia. Med Sci Monit. 25:6491–6503. 2019. View Article : Google Scholar : PubMed/NCBI
19	Ye X, Wei W, Zhang Z, He C, Yang R, Zhang J, Wu Z, Huang Q and Jiang Q: Identification of microRNAs associated with glioma diagnosis and prognosis. Oncotarget. 8:26394–26403. 2017. View Article : Google Scholar : PubMed/NCBI
20	Tesarova P, Kalousova M, Zima T and Tesar V: HMGB1, S100 proteins and other RAGE ligands in cancer-markers, mediators and putative therapeutic targets. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 160:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Jiang Z, Yan J and Ying S: HMGB1 as a potential biomarker and therapeutic target for malignant mesothelioma. Dis Markers. 2019:41831572019.PubMed/NCBI
22	Wu T, Zhang W, Yang G, Li H, Chen Q, Song R and Zhao L: HMGB1 overexpression as a prognostic factor for survival in cancer: A meta-analysis and systematic review. Dis Markers. 7:50417–50427. 2016.
23	Zhao Y, Yi J, Tao L, Huang G, Chu X, Song H and Chen L: Wnt signaling induces radioresistance through upregulating HMGB1 in esophageal squamous cell carcinoma. Cell Death Dis. 9:4332018. View Article : Google Scholar : PubMed/NCBI
24	Reed KR, Song F, Young MA, Hassan N, Antoine DJ, Gemici NB, Clarke AR and Jenkins JR: Secreted HMGB1 from Wnt activated intestinal cells is required to maintain a crypt progenitor phenotype. Oncotarget. 7:51665–51673. 2016. View Article : Google Scholar : PubMed/NCBI
25	Nagane M, Kobayashi K, Ohnishi A, Shimizu S and Shiokawa Y: Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. Jpn J Clin Oncol. 37:897–906. 2007. View Article : Google Scholar : PubMed/NCBI
26	Li C, Zou H, Wang Z, Tang X, Fan X, Zhang K, Liu J and Li Z: REST, not REST4, is a risk factor associated with radiotherapy plus chemotherapy efficacy in glioma. Drug Des Devel Ther. 12:1363–1371. 2018. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Wang S, Du S, Lv Y, Zhang F and Wang W: MicroRNA-665 inhibits the oncogenicity of retinoblastoma by directly targeting high-mobility group box 1 and inactivating the Wnt/β-catenin pathway. Cancer Manag Res. 11:3111–3123. 2019. View Article : Google Scholar : PubMed/NCBI
29	Zhang H, Li X, Meng W, Zhang L, Zhu X, Bai Z, Yan J and Zhou W: Overexpression of p16ink4a regulates the Wnt/beta-catenin signaling pathway in pancreatic cancer cells. Mol Med Rep. 17:2614–2618. 2018.PubMed/NCBI
30	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
31	Dehghan F, Boozarpour S, Torabizadeh Z and Alijanpour S: miR-21: A promising biomarker for the early detection of colon cancer. Onco Targets Ther. 12:5601–5607. 2019. View Article : Google Scholar : PubMed/NCBI
32	Ning S, Liu H, Gao B, Wei W, Yang A, Li J and Zhang L: miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. Oncol Lett. 18:3381–3387. 2019.PubMed/NCBI
33	Chen Y, Li ZH, Liu X, Liu GX, Yang HM and Wu PF: Reduced expression of miR-3653 in glioma and its correlations with clinical progression and patient survival. Eur Rev Med Pharmacol Sci. 23:6596–6601. 2019.PubMed/NCBI
34	Xu G, Fang P, Chen K, Xu Q, Song Z and Ouyang Z: MicroRNA-362-3p Targets PAX3 to Inhibit the Development of Glioma through Mediating Wnt/beta-Catenin Pathway. Neuroimmunomodulation. 26:119–128. 2019. View Article : Google Scholar : PubMed/NCBI
35	Wu M, Li X, Liu Q, Xie Y, Yuan J and Wanggou S: miR-526b-3p serves as a prognostic factor and regulates the proliferation, invasion, and migration of glioma through targeting WEE1. Cancer Manag Res. 11:3099–3110. 2019. View Article : Google Scholar : PubMed/NCBI
36	Sun X, Cui S, Fu X, Liu C, Wang Z and Liu Y: MicroRNA-146-5p promotes proliferation, migration and invasion in lung cancer cells by targeting claudin-12. Cancer Biomark. 25:89–99. 2019. View Article : Google Scholar : PubMed/NCBI
37	Chen S, Shi F, Zhang W, Zhou Y and Huang J: miR-744-5p inhibits non-small Cell lung cancer proliferation and invasion by directly targeting PAX2. Technol Cancer Res Treat. 18:15330338198769132019. View Article : Google Scholar : PubMed/NCBI
38	Wang J, Liu H, Zheng K, Zhang S and Dong W: MicroRNA-6852 suppresses glioma A172 cell proliferation and invasion by targeting LEF1. Exp Ther Med. 18:1877–1883. 2019.PubMed/NCBI
39	Zuo J, Yu H, Xie P, Liu W, Wang K and Ni H: miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma. Gene. 710:233–239. 2019. View Article : Google Scholar : PubMed/NCBI
40	Zhao XG, Hu JY, Tang J, Yi W, Zhang MY, Deng R, Mai SJ, Weng NQ, Wang RQ, Liu J, et al: miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 10:4792019. View Article : Google Scholar : PubMed/NCBI
41	Hu Y, Yang C, Yang S, Cheng F, Rao J and Wang X: miR-665 promotes hepatocellular carcinoma cell migration, invasion, and proliferation by decreasing Hippo signaling through targeting PTPRB. Cell Death Dis. 9:9542018. View Article : Google Scholar : PubMed/NCBI
42	Cao L, Jin H, Zheng Y, Mao Y, Fu Z, Li X and Dong L: DANCR-mediated microRNA-665 regulates proliferation and metastasis of cervical cancer through the ERK/SMAD pathway. Cancer Sci. 110:913–925. 2019. View Article : Google Scholar : PubMed/NCBI
43	Liu J, Jiang Y, Wan Y, Zhou S, Thapa S and Cheng W: MicroRNA665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10. Mol Med Rep. 18:2661–2668. 2018.PubMed/NCBI
44	Ma Y, Kang S, Wu X, Han B, Jin Z and Guo Z: Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells. Tumori. 104:338–343. 2018. View Article : Google Scholar : PubMed/NCBI
45	Li Y and Qin C: MiR-1179 inhibits the proliferation of gastric cancer cells by targeting HMGB1. Hum Cell. 32:352–359. 2019. View Article : Google Scholar : PubMed/NCBI
46	Zhang J, Zhang R, Lu WW, Zhu JS, Xia LQ, Lu YM and Chen NW: Clinical significance of hmgb1 expression in human gastric cancer. Int J Immunopathol Pharmacol. 27:543–551. 2014. View Article : Google Scholar : PubMed/NCBI
47	Angelopoulou E, Piperi C, Adamopoulos C and Papavassiliou AG: Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression. J Mol Med (Berl). 94:867–874. 2016. View Article : Google Scholar : PubMed/NCBI
48	Zhang J, Liu C and Hou R: Knockdown of HMGB1 improves apoptosis and suppresses proliferation and invasion of glioma cells. Chin J Cancer Res. 26:658–668. 2014.PubMed/NCBI